financetom
Business
financetom
/
Business
/
Walmart Fiscal Q1 to See 'Modest Upside' Despite Tariffs, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Walmart Fiscal Q1 to See 'Modest Upside' Despite Tariffs, Morgan Stanley Says
May 26, 2025 2:54 AM

11:12 AM EDT, 05/07/2025 (MT Newswires) -- Walmart ( WMT ) fiscal Q1 will see a "modest upside" to Wall Street's expectation despite near-term tariff uncertainty, however full year outlook may reflect a broader range of potential outcomes, Morgan Stanley said in a report Tuesday.

The company holds competitive advantages in scale, supply chain efficiency, category mix and pricing that make it one of the best retailers to manage these challenges and disruptions, according to the firm.

Morgan Stanley said US comparable store sales will exceed the consensus driven by improving consumer trends, strong grocery demand and higher Walmart+ membership.

Several non-recurring pressures, such as casualty claims, leap year comparison and Vizio consolidation, will drag on fiscal Q1 margins, but eCommerce profitability is improving, the firm added.

Morgan Stanley has an overweight rating on Walmart's ( WMT ) stock with a $115 price target.

Price: 98.83, Change: +0.28, Percent Change: +0.28

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
Jan 13, 2025
NEW YORK (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals ( REGN ), Illumina ( ILMN ) and 17 U.S. health systems will take a $320 million stake in the company as part of a deal to build the world's largest genetic database. The deal values privately held Truveta at more than $1 billion, it...
MDxHealth Estimates 28% Revenue Growth in Q4
MDxHealth Estimates 28% Revenue Growth in Q4
Jan 13, 2025
06:02 AM EST, 01/13/2025 (MT Newswires) -- MDxHealth ( MDXH ) said Monday it expects Q4 revenue to increase by 28% year over year to about $24.7 million. Five analysts polled by FactSet expect $23 million. For 2024, the company also projected a 28% revenue growth to $90 million. Analysts surveyed by FactSet expect $87.9 million. In addition, MDxHealth (...
Projected air traffic growth runs counter to climate goals, study says
Projected air traffic growth runs counter to climate goals, study says
Jan 13, 2025
DUBLIN, Jan 13 (Reuters) - Air passengers numbers are projected to more than double by 2050, boosting fuel demand and undermining the aviation industry's efforts to cut emissions, a study by climate advocacy group Transport and Environment suggested on Monday. As industry leaders meet at an annual finance conference this week in Dublin where many plane sales are expected, the...
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
Jan 13, 2025
NEW YORK, Jan 13 (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals ( REGN ) , Illumina ( ILMN ) and 17 U.S. health systems will take a $320 million stake in the company as part of a deal to build the world's largest genetic database. The deal values privately held Truveta at more than...
Copyright 2023-2026 - www.financetom.com All Rights Reserved